WuXi AppTec has acquired US-based clinical research services firm, Pharmapace, for an undisclosed sum.
Based in San Diego of California, Pharmapace has expertise in offering biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support.
Pharmapace will be included in WuXi AppTec’s clinical CRO arm WuXi Clinical, upon completion of the deal.
Pharmapace president and CEO Dr Larry Shen said: “Pharmapace is excited to join WuXi AppTec, a world-class organization with superior leadership and long history of success, a like-minded focus with a customer-centric approach, as well as a vision to enable every company to discover and develop drugs for the patients around the world.”
With clients in North America, Europe and Asia, the company offers a range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing.
The acquisition of Pharmapace will allow WuXi Clinical to expand its biometrics capabilities in the US and Europe.
The integrated teams of Pharmapace and WuXi Clinical China will provide cost effective biometrics service round the clock to the global customers.
Pharmapace’s addition will increase the employees of WuXi Clinical to 850 in China and the US.
The acquired business will also allow WuXi and its partners in Europe and Asia Pacific to offer customers with full clinical development services and serve as functional service provider (FSP) across the globe.
WuXi AppTec co-CEO Edward Hu said: “This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost effectively provide customers seamless biometrics services globally.
“Together, we are able to shorten time-to-market of new drugs and to achieve the dream that ‘every drug can be made and every disease can be treated’.”
WuXi AppTec is a pharmaceutical and medical device open-access capability and technology platform company with capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing.